Pentixapham Purchases Glycotope’s Discovery Unit

To increase its cancer pipeline, German radiopharmaceutical biotech Pentixapharm has purchased the target discovery unit of Glycotope, a German company, for an unknown fee.

Pentixapharm intends to develop radiopharmaceuticals from preclinical antibodies that target several cancer targets. The firm expanded its portfolio to include Glycotope’s labs, tools, cell banks, and cancer target database as well as the preclinical assets.

Pentixapharm CEO Hakim Bouterfa commented: “The acquisition will broaden Pentixapharm’s Intellectual Property portfolio beyond the one built around the CXCR4 receptor. This will immediately double the development pipeline and significantly expand the associated business and clinical development opportunities.”

He continued: “Glycotope’s pipeline comprises several candidates that can be used immediately for proof-of-concept studies as next-generation radiopharmaceuticals. We look forward to maximising the synergy of Pentixapharm’s know-how and Glycotope’s target discovery for the benefit of patients in both diagnostics and therapeutic applications.”

About 40 employees of Glycotope, comprising leaders, R&D experts, and executives, will join Pentixapharm as a result of the transaction.